full pdf of issue - Middle East Journal of Family Medicine

ORIGINAL CONTRIBUTION AND CLINICAL INVESTIGATION
26- Granai F, Smart HL
and Triger D. A study of the
penetration of meropenem into
bile using endoscopic retrograde
cholangiography. J Antimicrob.
Chemother.1992; 29 (6): 711-18.
27- Condon RE, Walker AP, Hanna
CB, Greenberg RN, Broom A and
Pitkin D. Penetration of meropenem
in plasma and abdominal tissues
from patients undergoing intraabdominal
surgery. Clin Infect Dis
1997; 24(Suppl 2):S181-183.
28- Ikawa K, Nakashima A,
Morikawa N, Ikeda K et al. Clinical
pharmacokinetics of meropenem
and biapenem in bile and dosing
considerations for biliary tract
infections based on site-specific
pharmacodynamic target attainment.
Antimicrob. Agents Chemother. 2011;
55(12): 5609-15.
29- Raghavan M and Linden PK.
Newer treatment options for skin and
soft tissue infections. Drugs 2004;
64:1621-42.
30- Embil JM, Soto NE, and
Melnick DA. A post hoc subgroup
analysis of meropenem versus
imipenem/cilastatin in a multicenter,
double-blind, randomized study of
complicated skin and skin-structure
infections in patients with diabetes
mellitus. Clin Therap 2006; 28:1164-
74.
31- Mohr JF. Update on the efficacy
and tolerability of meropenem in
the treatment of serious bacterial
infections. Clin Infect Diseases 2008;
47:S41-51.
32- Giske CG, Bore´n C, Wretlind
B and Kronvall G. Meropenem
susceptibility breakpoint for
Pseudomonas aeruginosa strains
hyperproducing mexB mRNA. Clin
Microbiol Infect 2005; 11: 662-9.
33- Wiskirchen DE, Koomanachai
P, Nicasio AM, Nicolau DP, and Kuti
JL. In vitro pharmacodynamics of
simulated pulmonary exposures of
tigecycline alone and in combination
against Klebsiella pneumonia isolates
producing a KPC carbapenemase.
Antimicrob Agents Chemother. 2010;
55(4): 1420-27.
34- Sueke H, Kaye S, Neal T, Murphy
C and Hall A. Minimum inhibitory
concentrations of standard and
novel antimicrobials for isolates from
bacterial keratitis. Invest Ophthalmol
Vis Sci. 2010; 51: 2519-24.
40
35- Hope R, Chaudhry A, Adkin R,
Guleri A, Williams S, Sharma R and
Livermore D. Minimum inhibitory
concentrations of meropenem
and doripenem for Pseudomonas
aeruginosa from the UK. European
Society of Clinical Microbiology and
Infectious Diseases 2011; Abstract
number: P1177.
36- Turner PJ and Edwards JR.
Activity of meropenem against
Enterococcus faecalis. J Antimicrob
Chemother 1997; 40:456-7.
37 - Mouton JW, Dudley MN, Cars
O, Derendorf H and Drusano GL.
Standardization of pharmacokinetic/
pharmacodynamics (PK/PD)
terminology for anti-infective drugs.
Int J Antimicrob Agents 2002; 19:355-
8.
38- Filho LS, Kuti JL and Nicolau
DP. Employing pharmacokinetic
and pharmacodynamics principles
to optimize antimicrobial treatment
in the face of emerging resistance.
Brazilian J Microbiol. 2007; 38:183-
93.
39- Vincent HT, Schilling AN, Shadi
N, Keith P, David AM and Elizabeth
AC. Optimization of Meropenem
minimum concentration/MIC ratio
to suppress in vitro resistance
of Pseudomonas aeruginosa.
Antimicrob Agents Chemother. 2005;
49 (12): 4920-7.
40- Smith BP, Cohen-Wolkowiez M,
Castro LM, Poindexter B, Bidegain
M, Weitkamp JH et al. Population
pharmacokinetics of meropenem in
plasma and cerebrospinal fluid of
infants with suspected or complicated
intra-abdominal infections. Pediat.
Infect. Dis. J. 2011; 30(10): 844-9.
41- Jaruratanasirikul S and
Sriwiriyajan S. Comparison of the
pharmacodynamics of meropenem
in healthy volunteers following
administration by intermittent infusion
or bolus injection. J. Antimicrob.
Chemother 2003; 52, 518-21.
42- Mattoes HM, Kuti JL, Drusano
GL and Nicolau DP. Optimizing
antimicrobial pharmacodynamics:
dosage strategies for meropenem.
Clin Ther 2004; 26:1187-98.
43- Odenholt-Tornqvist I. Studies
on the postantibiotic effect and
the postantibiotic sub-MIC effect
of meropenem J. Antimicrob.
Chemother 1993; 31 (6): 881-92.
MIDDLE EAST JOURNAL OF FAMILY MEDICINE VOLUME 10 ISSUE 6
MIDDLE EAST JOURNAL OF FAMILY MEDICINE • VOLUME 7, ISSUE 10
44- Mackenzie M, Gould IM,
Chapman DG and Jason D.
Postantibiotic effect of meropenem
on members of the family
Enterobacteriaceae determined by
five methods. Antimicrob Agents
Chemother. 1994; 38(11): 2583-9.
45-Novelli A, Fallani S, Cassetta MI,
Conti S, and Mazzei T. Postantibiotic
Leukocyte enhancement of
meropenem against Gram-positive
and Gram-negative Strains.
Antimicrob Agents Chemother 2000;
44(11): 3174-6.
46- Tomozawa T, Sugihara C, Kakuta
M, Sugihara K and Koga T. In vitro
postantibiotic effects of tomopenem
(CS-023) against Staphylococcus
aureus and Pseudomonas
aeruginosa. J. Med Microbiol 2010;
59 (4): 438-41.
47- Sharma KK, Sangraula H, and
Mediratta PK 2002. Some concepts
in antibacterial drug therapy. Indian J
Pharmacol. 2002; 34: 390-6.
48- Capitano B, Nicolau DP,
Potoski BA, et al. Meropenem
administered as a prolonged infusion
to treat serious gram-negative
central nervous system infections.
Pharmacotherapy 2004; 24:803-7.